Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tarsa Therapeutics Inc.

www.tarsatherapeutics.com

Latest From Tarsa Therapeutics Inc.

Merck Loses Chance For Primary Care Blockbuster With Odanacatib Failure

Termination of osteoporosis drug odanacatib due to stroke risk means a loss for Merck in reliving the glory days of branded Fosamax.

Clinical Trials Commercial

Will Radius Health's Abaloparatide Data Do The Trick In Osteoporosis?

Abaloparatide looks better for improving bone mass with less hypercalcemia than Lilly's first-in-class Forteo in the Phase III ACTIVE study, but it remains to be seen whether this will be enough to get ahead in the increasingly crowded osteoporosis market.

Clinical Trials Research & Development

Will Radius Health's Abaloparatide Data Do The Trick In Osteoporosis?

Abaloparatide looks better for improving bone mass with less hypercalcemia than Lilly's first-in-class Forteo in the Phase III ACTIVE study, but it remains to be seen whether this will be enough to get ahead in the increasingly crowded osteoporosis market.

Clinical Trials Research & Development

Amgen Files Osteoporosis Drug In US Ahead Of Rival Merck

Amgen Inc. and partner UCB Group have filed their osteoporosis drug romosozumab, which is anticipated to drive sales of more than $700m worldwide by 2023, in the US for the treatment of postmenopausal women at risk of fractures.

Commercial Biologics
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tarsa Therapeutics Inc.
  • Senior Management
  • Dave Brand, Pres. & CEO
    James P Gilligan, PhD, CSO
  • Contact Info
  • Tarsa Therapeutics Inc.
    Phone: (267) 273-7940
    1628 John F. Kennedy Blvd., Ste. 1400
    Philadelphia, PA 19103-2124
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register